Adgero Biopharmaceuticals

Adgero Biopharmaceuticals Adgero Biopharmaceuticals is leveraging its late stage photodynamic therapy (PDT) platform for the t Adgero Biopharmaceuticals Holdings, Inc.

is a privately-held biopharmaceutical company focused on building a pipeline by advancing its proprietary late stage photodynamic therapy ("PDT") platform with broad utility for the treatment of serious oncology indications. Its lead product candidate, REM-001 Therapy, has demonstrated promising safety and efficacy in four Phase 2/3 clinical studies in patients with cutaneous metastatic breast can

cer ("CMBC") who have failed radiation therapy. Use of Adgero's existing data or the completion of a Phase 3 trial in individuals with CMBC could lead to approval of REM-001 Therapy.

Address

Princeton, NJ
08850

Website

Alerts

Be the first to know and let us send you an email when Adgero Biopharmaceuticals posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Adgero Biopharmaceuticals:

Shortcuts

Share

Category